84 related articles for article (PubMed ID: 24610646)
1. FLT-PET in previously untreated patients with low-grade glioma can predict their overall survival.
Belohlavek O; Fencl P; Majovsky M; Jaruskova M; Benes V
Nucl Med Rev Cent East Eur; 2014; 17(1):7-12. PubMed ID: 24610646
[TBL] [Abstract][Full Text] [Related]
2. Comparison of 3'-deoxy-3'-[18F]fluorothymidine PET and O-(2-[18F]fluoroethyl)-L-tyrosine PET in patients with newly diagnosed glioma.
Jeong SY; Lim SM
Nucl Med Biol; 2012 Oct; 39(7):977-81. PubMed ID: 22483845
[TBL] [Abstract][Full Text] [Related]
3. 3'-Deoxy-3'-18F-fluorothymidine PET-derived proliferative volume predicts overall survival in high-grade glioma patients.
Idema AJ; Hoffmann AL; Boogaarts HD; Troost EG; Wesseling P; Heerschap A; van der Graaf WT; Grotenhuis JA; Oyen WJ
J Nucl Med; 2012 Dec; 53(12):1904-10. PubMed ID: 23077112
[TBL] [Abstract][Full Text] [Related]
4. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of 3'-deoxy-3'-18F-fluorothymidine ([(18)F] FLT PET) in patients with recurrent malignant gliomas.
Zhao F; Cui Y; Li M; Fu Z; Chen Z; Kong L; Yang G; Yu J
Nucl Med Biol; 2014 Sep; 41(8):710-5. PubMed ID: 24929963
[TBL] [Abstract][Full Text] [Related]
6. 11C-methionine (MET) and 18F-fluorothymidine (FLT) PET in patients with newly diagnosed glioma.
Hatakeyama T; Kawai N; Nishiyama Y; Yamamoto Y; Sasakawa Y; Ichikawa T; Tamiya T
Eur J Nucl Med Mol Imaging; 2008 Nov; 35(11):2009-17. PubMed ID: 18542957
[TBL] [Abstract][Full Text] [Related]
7. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors.
Jacobs AH; Thomas A; Kracht LW; Li H; Dittmar C; Garlip G; Galldiks N; Klein JC; Sobesky J; Hilker R; Vollmar S; Herholz K; Wienhard K; Heiss WD
J Nucl Med; 2005 Dec; 46(12):1948-58. PubMed ID: 16330557
[TBL] [Abstract][Full Text] [Related]
8. Early determination of prognosis by interim 3'-deoxy-3'-18F-fluorothymidine PET in patients with non-Hodgkin lymphoma.
Lee H; Kim SK; Kim YI; Kim TS; Kang SH; Park WS; Yun T; Eom HS
J Nucl Med; 2014 Feb; 55(2):216-22. PubMed ID: 24365650
[TBL] [Abstract][Full Text] [Related]
9. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
Kahraman D; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Holstein A; Dietlein M; Wolf J; Kobe C
J Nucl Med; 2011 Dec; 52(12):1871-7. PubMed ID: 22065872
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral heterogeneity of
Mitamura K; Yamamoto Y; Kudomi N; Maeda Y; Norikane T; Miyake K; Nishiyama Y
Ann Nucl Med; 2017 Jan; 31(1):46-52. PubMed ID: 27686469
[TBL] [Abstract][Full Text] [Related]
11. Glioma proliferation as assessed by 3'-fluoro-3'-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma.
Ullrich R; Backes H; Li H; Kracht L; Miletic H; Kesper K; Neumaier B; Heiss WD; Wienhard K; Jacobs AH
Clin Cancer Res; 2008 Apr; 14(7):2049-55. PubMed ID: 18381944
[TBL] [Abstract][Full Text] [Related]
12. 3'-deoxy-3'-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab.
Schwarzenberg J; Czernin J; Cloughesy TF; Ellingson BM; Pope WB; Geist C; Dahlbom M; Silverman DH; Satyamurthy N; Phelps ME; Chen W
J Nucl Med; 2012 Jan; 53(1):29-36. PubMed ID: 22159180
[TBL] [Abstract][Full Text] [Related]
13. Repeatability of
Lodge MA; Holdhoff M; Leal JP; Bag AK; Nabors LB; Mintz A; Lesser GJ; Mankoff DA; Desai AS; Mountz JM; Lieberman FS; Fisher JD; Desideri S; Ye X; Grossman SA; Schiff D; Wahl RL
J Nucl Med; 2017 Mar; 58(3):393-398. PubMed ID: 27688473
[TBL] [Abstract][Full Text] [Related]
14. Comparison of 18F-fluorodeoxyglucose and 18F-fluorothymidine PET in differentiating radiation necrosis from recurrent glioma.
Enslow MS; Zollinger LV; Morton KA; Butterfield RI; Kadrmas DJ; Christian PE; Boucher KM; Heilbrun ME; Jensen RL; Hoffman JM
Clin Nucl Med; 2012 Sep; 37(9):854-61. PubMed ID: 22889774
[TBL] [Abstract][Full Text] [Related]
15. Combining 3'-Deoxy-3'-[18F] fluorothymidine and MRI increases the sensitivity of glioma volume detection.
Fernandez P; Zanotti-Fregonara P; Eimer S; Gimbert E; Monteil P; Penchet G; Lamare F; Perez P; Vimont D; Ledure S; Tourdias T; Loiseau H
Nucl Med Commun; 2019 Oct; 40(10):1066-1071. PubMed ID: 31469809
[TBL] [Abstract][Full Text] [Related]
16. [Use of 11F-fluorothymidine positron emission tomography in brain tumor].
Kawai N; Kagawa M; Miyake K; Nishiyama Y; Yamamoto Y; Shiraishi H; Ichikawa T; Tamiya T
No Shinkei Geka; 2009 Jul; 37(7):657-64. PubMed ID: 19621774
[TBL] [Abstract][Full Text] [Related]
17. Kinetics of 3'-deoxy-3'-18F-fluorothymidine during treatment monitoring of recurrent high-grade glioma.
Schiepers C; Dahlbom M; Chen W; Cloughesy T; Czernin J; Phelps ME; Huang SC
J Nucl Med; 2010 May; 51(5):720-7. PubMed ID: 20395318
[TBL] [Abstract][Full Text] [Related]
18. Imaging of proliferation in hepatocellular carcinoma with the in vivo marker 18F-fluorothymidine.
Eckel F; Herrmann K; Schmidt S; Hillerer C; Wieder HA; Krause BJ; Schuster T; Langer R; Wester HJ; Schmid RM; Schwaiger M; Buck AK
J Nucl Med; 2009 Sep; 50(9):1441-7. PubMed ID: 19690030
[TBL] [Abstract][Full Text] [Related]
19. Can 3'-deoxy-3'-(18)F-fluorothymidine or 2'-deoxy-2'-(18)F-fluoro-d-glucose PET/CT better assess response after 3-weeks treatment by epidermal growth factor receptor kinase inhibitor, in non-small lung cancer patients? Preliminary results.
Bhoil A; Singh B; Singh N; Kashyap R; Watts A; Sarika S; Mittal BR
Hell J Nucl Med; 2014; 17(2):90-6. PubMed ID: 24997081
[TBL] [Abstract][Full Text] [Related]
20. PET/CT with 3'-deoxy-3'-[18F]fluorothymidine for lung cancer patients receiving carbon-ion radiotherapy.
Saga T; Koizumi M; Inubushi M; Yoshikawa K; Tanimoto K; Fukumura T; Miyamoto T; Nakajima M; Yamamoto N; Baba M
Nucl Med Commun; 2011 May; 32(5):348-55. PubMed ID: 21326122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
